Juno Therapeutics (JUNO) Earns News Impact Score of 0.19

News coverage about Juno Therapeutics (NASDAQ:JUNO) has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Juno Therapeutics earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.7078271962422 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

NASDAQ:JUNO remained flat at $$86.96 on Thursday. The company’s stock had a trading volume of 2 shares, compared to its average volume of 5,484,542. Juno Therapeutics has a 12-month low of $19.62 and a 12-month high of $87.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.61 and a quick ratio of 4.77.

A number of research firms recently issued reports on JUNO. BidaskClub cut Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. Leerink Swann cut Juno Therapeutics from an “outperform” rating to a “market perform” rating and lifted their price target for the company from $56.00 to $87.00 in a report on Tuesday, January 23rd. Raymond James cut Juno Therapeutics from an “outperform” rating to a “hold” rating in a report on Tuesday, January 23rd. SunTrust Banks reaffirmed a “hold” rating on shares of Juno Therapeutics in a report on Monday, January 22nd. Finally, Barclays cut Juno Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $55.00 to $87.00 in a report on Wednesday, January 24th. One analyst has rated the stock with a sell rating, eighteen have issued a hold rating and two have assigned a buy rating to the stock. Juno Therapeutics presently has a consensus rating of “Hold” and an average target price of $52.55.

In other Juno Therapeutics news, EVP Robert Azelby sold 3,497 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $85.77, for a total transaction of $299,937.69. Following the completion of the sale, the executive vice president now directly owns 93,771 shares of the company’s stock, valued at approximately $8,042,738.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 114,360 shares of company stock valued at $9,857,003 over the last three months. Company insiders own 15.08% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/19/juno-therapeutics-juno-earns-news-impact-score-of-0-19.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply